selected scholarly activity
-
academic article
- Optimizing the delivery of genetic and advanced diagnostic testing in the province of Ontario: challenges and implications for laboratory technology assessment and management in decentralized healthcare systems. Journal of Medical Economics Journal of Outcomes Research. 25:993-1004. 2022
- BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study. JTO Clinical and Research Reports. 3:100400-100400. 2022
- Physician and Surgeon Communication Assessed via the Pathology Requisition in a Regional Laboratory Over Ten Years. Cureus. 14:e27714. 2022
- Barriers to Access: Global Variability in Implementing Treatment Advances in Lung Cancer. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. 42:666-672. 2022
- Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease. Acta Oncologica. 61:705-713. 2022
- Role of Adjuvant Therapy in Esophageal Cancer Patients After Neoadjuvant Therapy and Esophagectomy. Annals of Surgery. 275:91-98. 2022
- The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 14:175883592211126-175883592211126. 2022
- Canadian Consensus Recommendations on the Management of MET-Altered NSCLC. Current Oncology. 28:4552-4576. 2021
- The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer. Current Oncology. 28:4392-4407. 2021
- Development and validation of a prediction model of poor performance status and severe symptoms over time in cancer patients (PROVIEW+). Palliative Medicine. 35:1713-1723. 2021
- IMPACT OF STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN OLIGOPROGRESSIVE METASTATIC DISEASE. Acta Oncologica. 163:S25-S25. 2021
- Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE. Journal of Nuclear Medicine. 62:1406-1414. 2021
- The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer. Lung Cancer. 160:136-151. 2021
- Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada. Lung Cancer. 157:40-47. 2021
- Evolution of anatomic pathology workload from 2011 to 2019 assessed in a regional hospital laboratory via 574,093 pathology reports. PLoS ONE. 16:e0253876-e0253876. 2021
- The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 13:175883592110563-175883592110563. 2021
- Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review. Journal of Patient-Reported Outcomes. 4:58. 2020
- Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer. Oncologist. 25:981-992. 2020
- A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies. Investigational New Drugs. 38:1442-1447. 2020
- Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial. The Lancet Oncology. 21:1066-1076. 2020
- A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. Lung Cancer. 143:1-11. 2020
- Canadian Consensus: A New Systemic Treatment Algorithm for Advanced EGFR-Mutated Non-Small-Cell Lung Cancer. Current Oncology. 27:146-155. 2020
- Development and Validation of a Prognostic Survival Model With Patient-Reported Outcomes for Patients With Cancer. Jama Network Open. 3:e201768-e201768. 2020
- Immuno-Oncology—The New Paradigm of Lung Cancer Treatment. Current Oncology. 27:78-86. 2020
- Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature Nature: New biology. 579:284-290. 2020
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. New England Journal of Medicine. 382:41-50. 2020
- Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer. Oncologist. 25:64-77. 2020
- Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer. Lung Cancer. 134:259-267. 2019
- Resource Use in the Last Three Months of Life by Lung Cancer Patients in Southern Ontario. Current Oncology. 26:247-252. 2019
- Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. Investigational New Drugs. 37:498-506. 2019
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. The Lancet. 393:1819-1830. 2019
- Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer. Current Oncology. 26:81-93. 2019
- Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort. Current Oncology. 25:384-392. 2018
- Canadian Perspectives: Update on Inhibition of ALK-Positive Tumours in Advanced Non-Small-Cell Lung Cancer. Current Oncology. 25:317-328. 2018
- Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC. Journal of Thoracic Oncology. 13:1363-1372. 2018
- Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC. Cancer Treatment Reviews. 65:65-77. 2018
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. The Lancet Oncology. 19:521-536. 2018
- Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer. Current Oncology. 25:73-82. 2018
- Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer. New England Journal of Medicine. 378:113-125. 2018
- A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC. EJNMMI Research. 7:8. 2017
- A Novel Neoadjuvant Therapy for Operable Locally Invasive Non–Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574). Clinical Lung Cancer. 18:436-440.e1. 2017
- Oncology care provider perspectives on exercise promotion in people with cancer: an examination of knowledge, practices, barriers, and facilitators. Supportive Care in Cancer. 25:2297-2304. 2017
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer. New England Journal of Medicine. 376:2415-2426. 2017
- Management of Egfr-Mutated Non-Small-Cell Lung Cancer: Practical Implications from a Clinical and Pathology Perspective. Current Oncology. 24:111-119. 2017
- Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck. Cancer Treatment Reviews. 54:43-57. 2017
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. The Lancet Oncology. 18:31-41. 2017
- Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non–Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. Clinical Lung Cancer. 18:34-42.e2. 2017
- Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. Frontiers in Oncology. 7:67. 2017
- Multidisciplinary Influence on Care of Lung Cancer Patients at the Time of Diagnosis: a Patient Survey. Clinical Oncology Comparative Haematology International. 28:667-667. 2016
- Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 34:2980-2987. 2016
- Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 34:2969-2979. 2016
- Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22:2897-2907. 2016
- Canadian Consensus: Inhibition of Alk-Positive Tumours in Advanced Non-Small-Cell Lung Cancer. Current Oncology. 23:196-200. 2016
- Pointed Progress in Second-Line Advanced Non–Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. Journal of Clinical Oncology. 34:1676-1688. 2016
- Imaging Biomarkers in Immunotherapy. Biomarkers in Cancer. 8s2:BIC.S31805-BIC.S31805. 2016
- Alterations of immune response of non-small cell lung cancer with Azacytidine. Oncotarget. 4:2067-2079. 2013
- A Phase I Study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer. Investigational New Drugs. 31:1244-1250. 2013
-
Phase II study of
TAS ‐106 in patients with platinum‐failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer. Cancer Medicine. 2:351-359. 2013 - Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 8:619-623. 2013
- Aberrant Epigenetic Regulation: A Central Contributor to Lung Carcinogenesis and a New Therapeutic Target. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. 33:e295-e300. 2013
- Method to Our Madness or Madness in Our Methods? Pitfalls in Trial Methodology. Journal of Clinical Oncology. 30:2025-2027. 2012
- A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer. 74:481-485. 2011
- Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung Cancer. Cancer Discovery. 1:598-607. 2011
- Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 29:1075-1082. 2011
- Bevacizumab in advanced lung cancer: in search of the right drug for the right patient.. Oncology. 24:1223-1226. 2010
- A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemotherapy and Pharmacology. 66:1079-1085. 2010
- Combined Modality Therapy of Esophageal Cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 6:851-861. 2008
- Targeting the epidermal growth factor receptor in non-small-cell lung cancer: Who, which, when, and how?. Current Oncology Reports. 9:255-264. 2007
- Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter. Cancer Chemotherapy and Pharmacology. 59:621-629. 2007
- Thirty years later: We've only just begun. Oncology. 20:1663-+. 2006
- Adjuvant Treatment in Non-Small Cell Lung Cancer: Where Are We Now?. Journal of the National Comprehensive Cancer Network : JNCCN. 4:595-600. 2006
- The Horiike/Saijo article reviewed. Oncology. 19:55-56. 2005
- Adjuvant therapy for resected non-small-cell lung cancer: Past, present, and future. Current Oncology Reports. 7:248-254. 2005
- Small-cell lung cancer: Current therapy and novel agents - The Horiike/Saijo article reviewed. Oncology. 19:55-56. 2005
-
chapter
- Effusions. 925-944. 2008
-
conference paper
- EP04.02-004 The Patient Impact of Liquid Biopsy - Health-Related Quality of Life in Patients Undergoing Liquid Biopsy for Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. S261-S262. 2022
- EP08.02-034 OCELOT - Osimertinib then Chemotherapy in EGFR+ Lung Cancer with Osi Third-line Rechallenge and Osimertinib for Uncommon EGFRm in 1L. Journal of Thoracic Oncology. S412-S413. 2022
- OCELOT - Osimertinib then Chemotherapy in EGFR plus Lung Cancer with Osi Third-line Rechallenge and Osimertinib for Uncommon EGFRm in 1L. Journal of Thoracic Oncology. S412-S413. 2022
- Prevalence of TTF-1 negative lung adenocarcinoma on lung core biopsy with EGFR, ALK and PD-L1 status. Virchows Archiv. S26-S26. 2022
- The Patient Impact of Liquid Biopsy - Health-Related Quality of Life in Patients Undergoing Liquid Biopsy for Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. S261-S262. 2022
- Abstract CT561: KeyVibe-003: Randomized, double-blind, phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC. Cancer Research. CT561-CT561. 2022
- 2021 Canadian Surgery Forum01. Design and validation of a unique endoscopy simulator using a commercial video game03. Is ethnicity an appropriate measure of health care marginalization?: A systematic review and meta-analysis of the outcomes of diabetic foot ulceration in the Aboriginal population04. Racial disparities in surgery — a cross-specialty matched comparison between black and white patients05. Starting late does not increase the risk of postoperative complications in patients undergoing common general surgical procedures06. Ethical decision-making during a health care crisis: a resource allocation framework and tool07. Ensuring stability in surgical training program leadership: a survey of program directors08. Introducing oncoplastic breast surgery in a community hospital09. Leadership development programs for surgical residents: a review of the literature10. Superiority of non-opioid postoperative pain management after thyroid and parathyroid operations: a systematic review and meta-analysis11. Timing of ERCP relative to cholecystectomy in patients with ductal gallstone disease12. A systematic review and meta-analysis of randomized controlled trials comparing intraoperative red blood cell transfusion strategies13. Postoperative outcomes after frail elderly preoperative assessment clinic: a single-institution Canadian perspective14. Selective opioid antagonists following bowel resection for prevention of postoperative ileus: a systematic review and meta-analysis15. Peer-to-peer coaching after bile duct injury16. Laparoscopic median arcuate ligament release: a video abstract17. Retroperitoneoscopic approach to adrenalectomy19. Endoscopic Zenker diverticulotomy: a video abstract20. Variability in surgeons’ perioperative management of pheochromocytomas in Canada21. The contribution of surgeon and hospital variation in transfusion practice to outcomes for patients undergoing elective gastrointestinal cancer surgery: a population-based analysis22. Perioperative transfusions for gastroesophageal cancers: risk factors and short- and long-term outcomes23. The association between frailty and time alive and at home after cancer surgery among older adults: a population-based analysis24. Psychological and workplace-related effects of providing surgical care during the COVID-19 pandemic in British Columbia, Canada25. Safety of venous thromboembolism prophylaxis in endoscopic retrograde cholangiopancreatography: a systematic review26. Complications and reintervention following laparoscopic subtotal cholecystectomy: a systematic review and meta-analysis27. Synchronization of pupil dilations correlates with team performance in a simulated laparoscopic team coordination task28. Receptivity to and desired design features of a surgical peer coaching program: an international survey9. Impact of the COVID-19 pandemic on rates of emergency department utilization due to general surgery conditions30. The impact of the current COVID-19 pandemic on the exposure of general surgery trainees to operative procedures31. Association between academic degrees and research productivity: an assessment of academic general surgeons in Canada32. Laparoscopic endoscopic cooperative surgery (LECS) for subepithelial gastric lesion: a video presentation33. Effect of the COVID-19 pandemic on acute care general surgery at an academic Canadian centre34. Opioid-free analgesia after outpatient general surgery: a pilot randomized controlled trial35. Impact of neoadjuvant immunotherapy or targeted therapies on surgical resection in patients with solid tumours: a systematic review and meta-analysis37. Surgical data recording in the operating room: a systematic review of modalities and metrics38. Association between nonaccidental trauma and neighbourhood socioeconomic status during the COVID-19 pandemic: a retrospective analysis39. Laparoscopic repair of a transdiaphragmatic gastropleural fistula40. Video-based interviewing in medicine: a scoping review41. Indocyanine green fluorescence angiography for prevention of anastomotic leakage in colorectal surgery: a cost analysis from the hospital payer’s perspective43. Perception or reality: surgical resident and faculty assessments of resident workload compared with objective data45. When illness and loss hit close to home: Do health care providers learn how to cope?46. Remote video-based suturing education with smartphones (REVISE): a randomized controlled trial47. The evolving use of robotic surgery: a population-based analysis48. Prophylactic retromuscular mesh placement for parastomal hernia prevention: a retrospective cohort study of permanent colostomies and ileostomies49. Intracorporeal versus extracorporeal anastomosis in laparoscopic right hemicolectomy: a retrospective cohort study on anastomotic complications50. A lay of the land — a description of Canadian academic acute care surgery models51. Emergency general surgery in Ontario: interhospital variability in structures, processes and models of care52. Trauma 101: a virtual case-based trauma conference as an adjunct to medical education53. Assessment of the National Surgical Quality Improvement Program Surgical Risk Calculator for predicting patient-centred outcomes of emergency general surgery patients in a Canadian health care system54. Sustainability of a narcotic reduction initiative: 1 year following the Standardization of Outpatient Procedure (STOP) Narcotics Study55. Barriers to transanal endoscopic microsurgery referral56. Geospatial analysis of severely injured rural patients in a geographically complex landscape57. Implementation of an incentive spirometry protocol in a trauma ward: a single-centre pilot study58. Impostor phenomenon is a significant risk factor for burnout and anxiety in Canadian resident physicians: a cross-sectional survey59. Understanding the influence of perioperative education on performance among surgical trainees: a single-centre experience60. The effect of COVID-19 pandemic on current and future endoscopic personal protective equipment practices: a national survey of 77 endoscopists61. Case report: delayed presentation of perforated sigmoid diverticulitis as necrotizing infection of the lower limb62. Investigating disparities in surgical outcomes in Canadian Indigenous populations63. Fundoplication is superior to medical therapy for Barrett esophagus disease regression and progression: a systematic review and meta-analysis64. Development of a novel online general surgery learning platform and a qualitative preimplementation analysis65. Hagfish slime exudate as a potential novel hemostatic agent: developing a standardized assessment protocol66. The effect of the first wave of the COVID-19 pandemic on surgical oncology case volumes and wait times67. Safety of same-day discharge in high-risk patients undergoing ambulatory general surgery68. External validation of the Codman score in colorectal surgery: a pragmatic tool to drive quality improvement69. Improved morbidity and gastrointestinal restoration rates without compromising survival rates for diverting loop ileostomy with colonic lavage versus total abdominal colectomy for fulminant Clostridioides difficile colitis: a multicentre retrospective cohort study70. Potential access to emergency general surgical care in Ontario71. Immersive virtual reality (iVR) improves procedural duration, task completion and accuracy in surgical trainees: a systematic review01. Clinical validation of the Canada Lymph Node Score for endobronchial ultrasound02. Venous thromboembolism in surgically treated esophageal cancer patients: a provincial population-based study03. Venous thromboembolism in surgically treated lung cancer patients: a population-based study04. Is frailty associated with failure to rescue after esophagectomy? A multi-institutional comparative analysis of outcomes05. Routine systematic sampling versus targeted sampling of lymph nodes during endobronchial ultrasound: a feasibility randomized controlled trial06. Gastric ischemic conditioning reduces anastomotic complications in patients undergoing esophagectomy: a systematic review and meta-analysis07. Move For Surgery, a novel preconditioning program to optimize health before thoracic surgery: a randomized controlled trial08. In case of emergency, go to your nearest emergency department — Or maybe not?09. Does preoperative SABR increase the risk of complications from lung cancer resection? A secondary analysis of the MISSILE trial10. Segmental resection for lung cancer: the added value of near-infrared fluorescence mapping diminishes with surgeon experience11. Toward competency-based continuing professional development for practising surgeons12. Stereotactic body radiotherapy versus surgery in older adults with NSCLC — a population-based, matched analysis of long-term dependency outcomes13. Role of adjuvant therapy in esophageal cancer patients after neoadjuvant therapy and curative esophagectomy: a systematic review and meta-analysis14. Evaluation of population characteristics on the incidence of thoracic empyema: an ecological study15. Determining the optimal stiffness colour threshold and stiffness area ratio cut-off for mediastinal lymph node staging using EBUS elastography and AI: a pilot study16. Quality assurance on the use of sequential compression stockings in thoracic surgery (QUESTs)17. The relationship between fissureless technique and prolonged air leak for patients undergoing video-assisted thoracoscopic lobectomy18. CXCR2 inhibition as a candidate for immunomodulation in the treatment of K-RAS-driven lung adenocarcinoma19. Assessment tools for evaluating competency in video-assisted thoracoscopic lobectomy: a systematic review20. Understanding the current practice on chest tube management following lung resection among thoracic surgeons across Canada21. Effect of routine jejunostomy tube insertion in esophagectomy: a systematic review and meta-analysis22. Recurrence of primary spontaneous pneumothorax following bullectomy with pleurodesis or pleurectomy: a retrospective analysis23. Surgical outcomes following chest wall resection and reconstruction24. Outcomes following surgical management of primary mediastinal nonseminomatous germ cell tumours25. Does robotic approach offer better nodal staging than thoracoscopic approach in anatomical resection for non–small cell lung cancer? A single-centre propensity matching analysis26. Competency assessment for mediastinal mass resection and thymectomy: design and Delphi process27. The contemporary significance of venous thromboembolism (deep venous thrombosis [DVT] and pulmonary embolus [PE]) in patients undergoing esophagectomy: a prospective, multicentre cohort study to evaluate the incidence and clinical outcomes of VTE after major esophageal resections28. Esophageal cancer: symptom severity at the end of life29. The impact of pulmonary artery reconstruction on postoperative and oncologic outcomes: a systematic review30. Association with surgical technique and recurrence after laparoscopic repair of paraesophageal hernia: a single-centre experience31. Enhanced recovery after surgery (ERAS) in esophagectomy32. Surgical treatment of esophageal cancer: trends in surgical approach and early mortality at a single institution over the past 18 years34. Adverse events and length of stay following minimally invasive surgery in paraesophageal hernia repair35. Long-term symptom control comparison of Dor and Nissen fundoplication following laparoscopic para-esophageal hernia repair: a retrospective analysis36. Willingness to pay: a survey of Canadian patients’ willingness to contribute to the cost of robotic thoracic surgery37. Radiomics in early-stage lung adenocarcinoma: a prediction tool for tumour immune microenvironments38. Effectiveness of intraoperative pyloric botox injection during esophagectomy: how often is endoscopic intervention required?39. An artificial intelligence algorithm for predicting lymph node malignancy during endobronchial ultrasound40. The effect of major and minor complications after lung surgery on length of stay and readmission41. Measuring cost of adverse events following thoracic surgery: a scoping review42. Laparoscopic paraesophageal hernia repair: characterization by hospital and surgeon volume and impact on outcomes43. NSQIP 5-Factor Modified Frailty Index predicts morbidity but not mortality after esophagectomy44. Trajectory of perioperative HRQOL and association with postoperative complications in thoracic surgery patients45. Variation in treatment patterns and outcomes for resected esophageal cancer at designated thoracic surgery centres46. Patient-reported pretreatment health-related quality of life (HRQOL) predicts short-term survival in esophageal cancer patients47. Analgesic efficacy of surgeon-placed paravertebral catheters compared with thoracic epidural analgesia after Ivor Lewis esophagectomy: a retrospective noninferiority study48. Rapid return to normal oxygenation after lung surgery49. Examination of local and systemic inflammatory changes during lung surgery01. Implications of near-infrared imaging and indocyanine green on anastomotic leaks following colorectal surgery: a systematic review and meta-analysis02. Repeat preoperative endoscopy after regional implementation of electronic synoptic endoscopy reporting: a retrospective comparative study03. Consensus-derived quality indicators for operative reporting in transanal endoscopic surgery (TES)04. Colorectal lesion localization practices at endoscopy to facilitate surgical and endoscopic planning: recommendations from a national consensus Delphi process05. Black race is associated with increased mortality in colon cancer — a population-based and propensity-score matched analysis06. Improved survival in a cohort of patients 75 years and over with FIT-detected colorectal neoplasms07. Laparoscopic versus open loop ileostomy reversal: a systematic review and meta-analysis08. Posterior mesorectal thickness as a predictor of increased operative time in rectal cancer surgery: a retrospective cohort study09. Improvement of colonic anastomotic healing in mice with oral supplementation of oligosaccharides10. How can we better identify patients with rectal bleeding who are at high risk of colorectal cancer?11. Assessment of long-term bowel dysfunction in rectal cancer survivors: a population-based cohort study12. Observational versus antibiotic therapy for acute uncomplicated diverticulitis: a noninferiority meta-analysis based on a Delphi consensus13. Radiotherapy alone versus chemoradiotherapy for stage I anal squamous cell carcinoma: a systematic review and meta-analysis14. Is the Hartmann procedure for diverticulitis obsolete? National trends in colectomy for diverticulitis in the emergency setting from 1993 to 201515. Sugammadex in colorectal surgery: a systematic review and meta-analysis16. Sexuality and rectal cancer treatment: a qualitative study exploring patients’ information needs and expectations on sexual dysfunction after rectal cancer treatment17. Video-based interviews in selection process18. Impact of delaying colonoscopies during the COVID-19 pandemic on colorectal cancer detection and prevention19. Opioid use disorder associated with increased anastomotic leak and major complications after colorectal surgery20. Effectiveness of a rectal cancer education video on patient expectations21. Robotic-assisted rectosigmoid and rectal cancer resection: implementation and early experience at a Canadian tertiary centre22. An online educational app for rectal cancer survivors with low anterior resection syndrome: a pilot study23. The effects of surgeon specialization on the outcome of emergency colorectal surgery24. Outcomes after colorectal cancer resections in octogenarians and older in a regional New Zealand setting — What are the predictors of mortality?25. Long-term outcomes after seton placement for perianal fistulae with and without Crohn disease26. A survey of patient and surgeon preference for early ileostomy closure following restorative proctectomy for rectal cancer — Why aren’t we doing it?27. Crohn disease independently associated with longer hospital admission after surgery28. Short-stay (≤ 1 d) diverting loop ileostomy closure can be selectively implemented without an increase in readmission and complication rates: an ACS-NSQIP analysis29. A comparison of perineal stapled rectal prolapse resection and the Altemeier procedure at 2 Canadian academic hospitals30. Mental health and substance use disorders predict 90-day readmission and postoperative complications following rectal cancer surgery31. Early discharge after colorectal cancer resection: trends and impact on patient outcomes32. Oral antibiotics without mechanical bowel preparation prior to emergency colectomy reduces the risk of organ space surgical site infections: a NSQIP propensity score matched study33. The impact of robotic surgery on a tertiary care colorectal surgery program, an assessment of costs and short-term outcomes — a Canadian perspective34. Should we scope beyond the age limit of guidelines? Adenoma detection rates and outcomes of screening and surveillance colonoscopies in patients aged 75–79 years35. Emergency department admissions for uncomplicated diverticulitis: a nationwide study36. Obesity is associated with a complicated episode of acute diverticulitis: a nationwide study37. Green indocyanine angiography for low anterior resection in patients with rectal cancer: a prospective before-and-after study38. The impact of age on surgical recurrence of fibrostenotic ileocolic Crohn disease39. A qualitative study to explore the optimal timing and approach for the LARS discussion01. Racial, ethnic and socioeconomic disparities in diagnosis, treatment and survival of patients with breast cancer: a SEER-based population analysis02. First-line palliative chemotherapy for esophageal and gastric cancer: practice patterns and outcomes in the general population03. Frailty as a predictor for postoperative outcomes following pancreaticoduodenectomy04. Synoptic electronic operative reports identify practice variation in cancer surgery allowing for directed interventions to decrease variation05. The role of Hedgehog signalling in basal-like breast cancer07. Clinical and patient-reported outcomes in oncoplastic breast conservation surgery from a single surgeon’s practice in a busy community hospital in Canada08. Upgrade rate of atypical ductal hyperplasia: 10 years of experience and predictive factors09. Time to first adjuvant treatment after oncoplastic breast reduction10. Preparing to survive: improving outcomes for young women with breast cancer11. Opioid prescription and consumption in patients undergoing outpatient breast surgery — baseline data for a quality improvement initiative12. Rectal anastomosis and hyperthermic intraperitoneal chemotherapy: Should we avoid diverting loop ileostomy?13. Delays in operative management of early-stage, estrogen-receptor positive breast cancer during the COVID-19 pandemic — a multi-institutional matched historical cohort study14. Opioid prescribing practices in breast oncologic surgery15. Oncoplastic breast reduction (OBR) complications and patient-reported outcomes16. De-escalating breast cancer surgery: Should we apply quality indicators from other jurisdictions in Canada?17. The breast cancer patient experience of telemedicine during COVID-1918. A novel ex vivo human peritoneal model to investigate mechanisms of peritoneal metastasis in gastric adenocarcinoma (GCa)19. Preliminary uptake and outcomes utilizing the BREAST-Q patient-reported outcomes questionnaire in patients following breast cancer surgery20. Routine elastin staining improves detection of venous invasion and enhances prognostication in resected colorectal cancer21. Analysis of exhaled volatile organic compounds: a new frontier in colon cancer screening and surveillance22. A clinical pathway for radical cystectomy leads to a shorter hospital stay and decreases 30-day postoperative complications: a NSQIP analysis23. Fertility preservation in young breast cancer patients: a population-based study24. Investigating factors associated with postmastectomy unplanned emergency department visits: a population-based analysis25. Impact of patient, tumour and treatment factors on psychosocial outcomes after treatment in women with invasive breast cancer26. The relationship between breast and axillary pathologic complete response in women receiving neoadjuvant chemotherapy for breast cancer01. The association between bacterobilia and the risk of postoperative complications following pancreaticoduodenectomy02. Surgical outcome and quality of life following exercise-based prehabilitation for hepatobiliary surgery: a systematic review and meta-analysis03. Does intraoperative frozen section and revision of margins lead to improved survival in patients undergoing resection of perihilar cholangiocarcinoma? A systematic review and meta-analysis04. Prolonged kidney procurement time is associated with worse graft survival after transplantation05. Venous thromboembolism following hepatectomy for colorectal metastases: a population-based retrospective cohort study06. Association between resection approach and transfusion exposure in liver resection for gastrointestinal cancer07. The association between surgeon volume and use of laparoscopic liver resection for gastrointestinal cancer08. Immune suppression through TIGIT in colorectal cancer liver metastases09. “The whole is greater than the sum of its parts” — a combined strategy to reduce postoperative pancreatic fistula after pancreaticoduodenectomy10. Laparoscopic versus open synchronous colorectal and hepatic resection for metastatic colorectal cancer11. Identifying prognostic factors for overall survival in patients with recurrent disease following liver resection for colorectal cancer metastasis12. Modified Blumgart pancreatojejunostomy with external stenting in laparoscopic Whipple reconstruction13. Laparoscopic versus open pancreaticoduodenectomy: a single centre’s initial experience with introduction of a novel surgical approach14. Neoadjuvant chemotherapy versus upfront surgery for borderline resectable pancreatic cancer: a single-centre cohort analysis15. Thermal ablation and telemedicine to reduce resource utilization during the COVID-19 pandemic16. Cost-utility analysis of normothermic machine perfusion compared with static cold storage in liver transplantation in the Canadian setting17. Impact of adjuvant therapy on overall survival in early-stage ampullary cancers: a single-centre retrospective review18. Presence of biliary anaerobes enhances response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma19. How does tumour viability influence the predictive capability of the Metroticket model? Comparing predicted-to-observed 5-year survival after liver transplant for hepatocellular carcinoma20. Does caudate resection improve outcomes in patients undergoing curative resection for perihilar cholangiocarcinoma? A systematic review and meta-analysis21. Appraisal of multivariable prognostic models for postoperative liver decompensation following partial hepatectomy: a systematic review22. Predictors of postoperative liver decompensation events following resection in patients with cirrhosis and hepatocellular carcinoma: a population-based study23. Characteristics of bacteriobilia and impact on outcomes after Whipple procedure01. Inverting the y-axis: the future of MIS abdominal wall reconstruction is upside down02. Progressive preoperative pneumoperitoneum: a single-centre retrospective study03. The role of radiologic classification of parastomal hernia as a predictor of the need for surgical hernia repair: a retrospective cohort study04. Comparison of 2 fascial defect closure methods for laparoscopic incisional hernia repair01. Hypoalbuminemia predicts serious complications following elective bariatric surgery02. Laparoscopic adjustable gastric band migration inducing jejunal obstruction associated with acute pancreatitis: aurgical approach of band removal03. Can visceral adipose tissue gene expression determine metabolic outcomes after bariatric surgery?04. Improvement of kidney function in patients with chronic kidney disease and severe obesity after bariatric surgery: a systematic review and meta-analysis05. A prediction model for delayed discharge following gastric bypass surgery06. Experiences and outcomes of Indigenous patients undergoing bariatric surgery: a mixed-methods scoping review07. What is the optimal common channel length in revisional bariatric surgery?08. Laparoscopic management of internal hernia in a 34-week pregnant woman09. Characterizing timing of postoperative complications following elective Roux-en-Y gastric bypass and sleeve gastrectomy10. Canadian trends in bariatric surgery11. Common surgical stapler problems and how to correct them12. Management of choledocholithiasis following Roux-en-Y gastric bypass: a systematic review and meta-analysis. Canadian Journal of Surgery. S80-S159. 2021
- 459 Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1–positive metastatic NSCLC. Journal for ImmunoTherapy of Cancer. A488-A488. 2021
- Does Tumor Response Correlate With Quality of Life Changes Following LU177 DOTATATE Therapy for Neuroendocrine Tumors? Observations From a Multicenter Prospective Study (NCT02743741). International Journal of Radiation Oncology Biology Physics. e81-e82. 2021
- Impact of Stereotactic Body Radiotherapy (SBRT) in Oligoprogressive Metastatic Disease. International Journal of Radiation Oncology Biology Physics. e479-e479. 2021
- 52: Impact of Stereotactic Body Radiotherapy (SBRT) in Oligoprogressive Metastatic Disease. Radiotherapy and Oncology. S25-S25. 2021
- Effects of ALK Tyrosine Kinase Inhibitors in the Treatment of Metastatic NSCLC: A Systematic Review and Meta-Analysis. Journal of Thoracic Oncology. S1089-S1090. 2021
- OA16.02 The Economic Value of Liquid Biopsy for Genomic Profiling in Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. S876-S876. 2021
- P14.01 Phase 3 Study of First-Line Pembrolizumab ± Vibostolimab (anti-TIGIT) in Patients With PD-L1‒Positive Metastatic NSCLC. Journal of Thoracic Oncology. S1010-S1011. 2021
- P45.10 Effects of ALK Tyrosine Kinase Inhibitors in the Treatment of Metastatic NSCLC: A Systematic Review and Meta-Analysis. Journal of Thoracic Oncology. S1089-S1090. 2021
- Phase 3 Study of First-Line Pembrolizumab +/- Vibostolimab (anti-TIGIT) in Patients With PD-L1-Positive Metastatic NSCLC. Journal of Thoracic Oncology. S1010-S1011. 2021
- Role of adjuvant therapy in esophageal cancer patients after neoadjuvant therapy and curative esophagectomy: A systematic review and meta-analysis.. Journal of Clinical Oncology. e16083-e16083. 2021
- The PROVIEW+ tool: Developing and validating a tool to predict risk of poor performance status and severe symptoms in cancer patients over time.. Journal of Clinical Oncology. 12095-12095. 2021
- Clinical Activity of BMS-986012, an AntieFucosyl-GM1 Monoclonal Antibody, Plus Nivolumab in Small Cell Lung Cancer. Journal of Thoracic Oncology. S195-S195. 2021
- Demonstrating VALUE of Liquid Biopsy for Lung Cancer in a Public Healthcare System. Journal of Thoracic Oncology. S689-S689. 2021
- FP03.03 Clinical Activity of BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody, Plus Nivolumab in Small Cell Lung Cancer. Journal of Thoracic Oncology. S195-S195. 2021
- P89.03 Demonstrating VALUE of Liquid Biopsy for Lung Cancer in a Public Healthcare System. Journal of Thoracic Oncology. S689-S689. 2021
- Optimizing the SPECT Imaging Workflow For Individualized Dosimetry in Lu177-DOTATATE Treatment Of Progressive Metastatic Neoendocrine Tumors. International Journal of Radiation Oncology Biology Physics. e588-e589. 2020
- 1195P The value of detecting resistance through liquid biopsy. Annals of Oncology. S786-S787. 2020
- 152: Toxicity Assessment of Individualized Dosimetry Adjusted PRRT - Interim Report of the Ontario Consortium Trial OZM 067. Radiotherapy and Oncology. S65-S66. 2020
- TOXICITY ASSESSMENT OF INDIVIDUALIZED DOSIMETRY ADJUSTED PRRT - INTERIM REPORT OF THE ONTARIO CONSORTIUM TRIAL OZM 067. Radiotherapy and Oncology. S65-S66. 2020
- Abstract A26: Defining VALUE: Routine liquid biopsy in NSCLC diagnosis—a Canadian trial in progress. Clinical Cancer Research. A26-A26. 2020
- Defining VALUE: Routine liquid biopsy in NSCLC diagnosis-a Canadian trial in progress. Clinical Cancer Research. 47-48. 2020
- Demonstrating the value of liquid biopsy for lung cancer in a public health care system.. Journal of Clinical Oncology. 3546-3546. 2020
- Demonstrating the value of liquid biopsy for lung cancer in a public health care system.. Journal of Clinical Oncology. 2020
- Development and validation of a risk prediction model for poor performance status and severe symptoms among cancer patients.. Journal of Clinical Oncology. 12097-12097. 2020
- Two-year survival with nivolumab in previously treated, advanced non-small cell lung cancer: A pooled analysis of real-world patients from France, Germany and Canada.. Journal of Clinical Oncology. e21714-e21714. 2020
- Two-year survival with nivolumab in previously treated, advanced non-small cell lung cancer: A pooled analysis of real-world patients from France, Germany and Canada.. Journal of Clinical Oncology. 2020
- Real-world outcomes for metastatic non-small cell lung cancer patients treated with checkpoint inhibitor immunotherapy in Canada. Journal of Clinical Oncology. 2020
- Real-world outcomes for metastatic non-small cell lung cancer patients treated with checkpoint inhibitor immunotherapy in Canada.. Journal of Clinical Oncology. 54-54. 2020
- 70 Quantifying Tumour Dose Using Individualized Dosimetry Methodology in 177LU Dotatate Therapy. Radiotherapy and Oncology. S32-S32. 2019
- MA11.04 Platinum Doublet + Durvalumab +/- Tremelimumab in Patients with Advanced NSCLC: A CCTG Phase IB Study - IND.226. Journal of Thoracic Oncology. S291-S292. 2019
- P1.01-55 Updated Analysis of Outcomes by Histology vs Cytology PD-L1 22C3 Antibody Testing in Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. S379-S380. 2019
- Pharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy. Annals of Oncology. v179-v179. 2019
- Pharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND226 study of durvalumab +/- tremelimumab in combination with platinum-doublet chemotherapy. Annals of Oncology. 2019
- QUANTIFYING TUMOUR DOSE USING INDIVIDUALIZED DOSIMETRY METHODOLOGY IN 177LU DOTATATE THERAPY. Radiotherapy and Oncology. S32-S32. 2019
- Communication with pathology evaluated via the pathology requisition using 396,033 pathology reports. Virchows Archiv. S133-S134. 2019
- Quantifying Renal And Tumor Doses with Individualized Dosimetry In 177Lu DOTATATE Therapy – What Difference Does It Make?. International Journal of Radiation Oncology Biology Physics. S205-S205. 2019
- Visceral pleural invasion by tumour size, cancer type and pathologist in 1,560 resections. Virchows Archiv. S42-S43. 2019
- A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies.. Journal of Clinical Oncology. 2599-2599. 2019
- A phase I study of [225Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors.. Journal of Clinical Oncology. TPS3152-TPS3152. 2019
- Individualized dosimetry for Lu177 DOTATATE therapy - What difference does it make?. Journal of Nuclear Medicine. 2019
- Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice. Annals of Oncology. ii65-ii65. 2019
- MA02.11 Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - A Prospective Canadian Study (VALUE). Journal of Thoracic Oncology. S362-S362. 2018
- P1.01-02 Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012. Journal of Thoracic Oncology. S458-S458. 2018
- P1.09-04 Optimization of PD-L1 Testing Specimen Flow in the Greater Hamilton, Ontario Region. Journal of Thoracic Oncology. S551-S551. 2018
- P2.09-08 Clinical Outcomes of Histology Versus Cytology PD-L1 22C3 Antibody Testing in Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. S764-S764. 2018
- P2.13-13 Real-World Study of Osimertinib in EGFR T790M-Mutated Non-Small Cell Lung Cancer (NSCLC): ASTRIS Canadian Cohort Analysis. Journal of Thoracic Oncology. S803-S803. 2018
- The use of patient reported outcome (PRO) instruments in immune checkpoint inhibitor (ICI) therapy for cancer: A systematic review. Annals of Oncology. viii690-viii690. 2018
- 200PD High physician confidence does not predict rate or type of treatment change for cases discussed at a thoracic multidisciplinary cancer conference: A case series in a tertiary cancer center. Journal of Thoracic Oncology. S120-S120. 2018
- MA 10.01 Durvalumab ± Tremelimumab with Platinum-Doublets in Non-Small Cell Lung Cancer: Canadian Cancer Trials Group Study IND.226. Journal of Thoracic Oncology. S1839-S1839. 2017
- OA 17.03 First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update. Journal of Thoracic Oncology. S1792-S1793. 2017
- P2.07-029 CheckMate 169: Safety/Efficacy of Nivolumab in Canadian Pretreated Advanced NSCLC (including Elderly and PS 2) Patients. Journal of Thoracic Oncology. S2426-S2427. 2017
- Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC). Annals of Oncology. 2017
- Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC). Annals of Oncology. v539-v539. 2017
- Immune related adverse events (irAE) with platinum chemotherapy (CT) with durvalumab (D) ± tremelimumab (T): CCTG IND226.. Journal of Clinical Oncology. 3058-3058. 2017
- Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012.. Journal of Clinical Oncology. 9093-9093. 2017
- MA09.03 Cisplatin/Pemetrexed + Durvalumab +/- Tremelimumab in Pts with Advanced Non-Squamous NSCLC: A CCTG Phase IB Study - IND.226. Journal of Thoracic Oncology. S392-S393. 2017
- OA03.01 First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012. Journal of Thoracic Oncology. S250-S251. 2017
- A Canadian Cancer Trials Group phase IB study of durvalumab with or without tremelimumab + standard platinum-doublet chemotherapy in patients with advanced, incurable solid malignancies (IND.226). European Journal of Cancer. S95-S95. 2016
- CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC. Journal of Thoracic Oncology. S250-S251. 2016
- ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC. Journal of Thoracic Oncology. S250-S251. 2016
- NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC. Annals of Oncology. vi577-vi577. 2016
- Comparison of Three Commercially Available Platforms for Somatic Mutation Profiling in Solid Tumors. Cancer Genetics and Cytogenetics. 287-287. 2016
- CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC.. Journal of Clinical Oncology. 3001-3001. 2016
- 3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses. European Journal of Cancer. S632-S632. 2015
- 3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC). European Journal of Cancer. S632-S633. 2015
- Safety and Efficacy of First-Line Nivolumab (NIVO; Anti-Programmed Death-1 [PD-1]) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. S176-S176. 2015
- A phase Ib study of selumetinib in patients (pts) with previously untreated metastatic Non-Small Cell Lung Cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group IND.215. NCT01783197.. Journal of Clinical Oncology. 2015
- A phase Ib study of selumetinib in patients (pts) with previously untreated metastatic Non-Small Cell Lung Cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group IND.215. NCT01783197.. Journal of Clinical Oncology. 8046-8046. 2015
- First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression.. Journal of Clinical Oncology. 8025-8025. 2015
- First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression.. Journal of Clinical Oncology. 2015
- NIVOLUMAB AND IPILIMUMAB IN FIRST-LINE NON-SMALL-CELL LUNG CARCINOMA (NSCLC): INTERIM PHASE I RESULTS. Asia-Pacific Journal of Clinical Oncology. 155-155. 2014
- First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status. International Journal of Radiation Oncology Biology Physics. S31-S31. 2014
- Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics. S2-S2. 2014
- Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics. S32-S33. 2014
- NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH PLATINUM-BASED DOUBLET CHEMOTHERAPY (PT-DC) OR ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC). Journal of Thoracic Oncology. S153-S153. 2014
- Nivolumab (Anti-Pd-1; Bms-936558, Ono-4538) in Combination with Platinum-Based Doublet Chemotherapy (Pt-Dc) or Erlotinib (Erl) in Advanced Non-Small Cell Lung Cancer (Nsclc). Annals of Oncology. iv363-iv363. 2014
- First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.. Journal of Clinical Oncology. 8024-8024. 2014
- First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.. Journal of Clinical Oncology. 2014
- Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results.. Journal of Clinical Oncology. 8023-8023. 2014
- Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 8113-8113. 2014
- A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). Journal of Clinical Oncology. 2013
- A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts).. Journal of Clinical Oncology. 8072-8072. 2013
- Predicting sensitivity to azacytidine in non-small cell cancer lines by absence of activating mutations.. Journal of Clinical Oncology. e18147-e18147. 2012
- Predicting sensitivity to azacytidine in non-small cell cancer lines by absence of activating mutations.. Journal of Clinical Oncology. 2012
- Abstract ED03-04: Using epigenetic biomarkers as prognostic and predictive markers in non-small cell lung cancer (NSCLC) and the promise of epigenetic therapy. Cancer Epidemiology Biomarkers and Prevention. ed03-04-ed03-04. 2011
- BIOMARKER DEVELOPMENT FOR A PHASE II STUDY OF COMBINATION EPIGENETIC THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC). Journal of Thoracic Oncology. S1101-S1101. 2011
- A phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer.. Journal of Clinical Oncology. e14644-e14644. 2011
- Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.. Journal of Clinical Oncology. 3098-3098. 2011
- Abstract LB-411: A phase II study of combination epigenetic therapy in advanced non-small cell lung cancer. Cancer Research. 2011
- Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.. Journal of Clinical Oncology. 3016-3016. 2010
- Phase II study of neoadjuvant and adjuvant gefitinib (G) with neoadjuvant chemoradiotherapy (CRT) in operable esophageal adenocarcinoma (EAC).. Journal of Clinical Oncology. e14532-e14532. 2010
- A phase II trial of 5-azacitidine (5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer (NSCLC): an interim analysis. Journal of Thoracic Oncology. S306-S307. 2009
- Interim analysis of a phase II trial of 5-azacitidine (5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer (NSCLC). Journal of Clinical Oncology. 8055-8055. 2009
- Interim analysis of a phase II trial of 5-azacitidine (5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer (NSCLC). Journal of Clinical Oncology. 2009
- Phase I trial of 5-azacitidine (5AC) and SNDX-275 in advanced lung cancer (NSCLC). Journal of Clinical Oncology. 19036-19036. 2008
- Gemcitabine (G) and vinorelbine (V) in patients (pts) with recurrent advanced non-small cell lung cancer (NSCLC): Sequence of administration matters. Journal of Clinical Oncology. 17101-17101. 2006